Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.
-
Upload
prudence-adams -
Category
Documents
-
view
265 -
download
18
Transcript of Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.
![Page 1: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/1.jpg)
Harvoni®
ledipasvir/sofosbuvir
Manufacturer: Gilead Sciences
FDA Approval Date: 10/10/2014
![Page 2: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/2.jpg)
Harvoni® - ledipasvir/sofosbuvir
Clinical Application
• Indication:• Treatment of chronic hepatitis C (CHC)
genotype 1 infection in adults.
• Place in therapy:• One pill a day for convenient dosing and
increased compliance
• Less adverse effects than the current treatment options for genotype 1
![Page 3: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/3.jpg)
Harvoni® - ledipasvir/sofosbuvir
Clinical Application
• Contraindications:• None
• Warnings and Precautions:• P-gp inducers may reduce therapeutic
effect of Harvoni.
• The use of Harvoni with other products containing sofosbuvir (Sovaldi) is not recommended.
![Page 4: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/4.jpg)
Harvoni® - ledipasvir/sofosbuvir
Clinical Application
• Pregnancy:• Category B
• Lactation:• It is not known whether Harvoni can be
found in human breast milk.
![Page 5: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/5.jpg)
Harvoni® - ledipasvir/sofosbuvir
Drug Facts
• Pharmacology:• Ledipasvir – inhibits the HCV NS5A
protein necessary for viral replication
• Sofosbuvir – prodrug converted to its active form (GS-461203), which inhibits NS5B RNA-dependent RNA polymerase and acts as a chain terminator
![Page 6: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/6.jpg)
Harvoni® - ledipasvir/sofosbuvir
Drug Facts
• Pharmacokinetics:
ACmax 4-4.5 hoursWell absorbed
D >99.8% protein bound
M Slow oxidative metabolism via an unknown mechanism
E87% feces, 1% urineT1/2 47 hours
![Page 7: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/7.jpg)
Harvoni® - ledipasvir/sofosbuvir
Drug Interactions
• Drug Interactions – Object Drugs: digoxin tenofovir simeprevir rosuvastatin
![Page 8: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/8.jpg)
Harvoni® - ledipasvir/sofosbuvir
Drug Interactions
• Drug Interactions – Precipitant Drugs: • Acid reducing agents solubility of
ledipasvir
• Anticonvulsants Harvoni
• Antimycobacterials Harvoni
• HCV products ledipasvir
• St. Johns wort Harvoni
![Page 9: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/9.jpg)
Harvoni® - ledipasvir/sofosbuvir
Adverse Effects
Harvoni8 weeks
Harvoni12 weeks
Harvoni 24 weeks
Fatigue 16% 13% 18%
Headache 11% 14% 17%
Nausea 6% 7% 9%
Diarrhea 4% 3% 7%
Insomnia 3% 5% 6%
![Page 10: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/10.jpg)
Harvoni® - ledipasvir/sofosbuvir
Monitoring Parameters
• Efficacy Monitoring:• Signs of clinical improvement
• HCV RNA (viral load) at weeks 4 and 12
• Toxicity Monitoring:• CBC, basic chemistry panel, liver enzyme
levels, bilirubin levels at weeks 1-2, 4, and then monthly during treatment
![Page 11: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/11.jpg)
Harvoni® - ledipasvir/sofosbuvir
Prescription Information
• Dosing:• One tablet (90mg ledipasvir/400mg
sofosbuvir) taken orally once daily with or without food
• Treatment-naïve with or without cirrhosis: 12 weeks
• Treatment-experienced without cirrhosis: 12 weeks
• Treatment-experienced with cirrhosis: 24 weeks
![Page 12: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/12.jpg)
Harvoni® - ledipasvir/sofosbuvir
Prescription Information
Duration of Treatment Estimated Cost
8 Weeks $63,000
12 Weeks $94,500
24 Weeks $189,000
*Estimated cost based on Wholesaler Acquisition Cost of $1125 per pill
![Page 13: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/13.jpg)
Harvoni® - ledipasvir/sofosbuvir
Literature Review
ION-1
•Design: open-label, randomized, phase 3 trial
• 99 sites in the United States and Europe
•Interventions• Fixed-dose combinations of
ledipasvir/sofosbuvir +/- ribavirin for 12 or 24 weeks in treatment-naïve patients with genotype 1 HCV
Afdhal N, et al. N Engl J Med. 2014;370:1889-98.
![Page 14: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/14.jpg)
Harvoni® - ledipasvir/sofosbuvir
Literature Review
ION-1
•Primary Endpoint: SVR at 12 weeks after the end of treatment
• Assessed in all patients who were randomized and received treatment
Afdhal N, et al. N Engl J Med. 2014;370:1889-98.
![Page 15: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/15.jpg)
Harvoni® - ledipasvir/sofosbuvir
Literature Review
ION-1
•Inclusion Criteria:• Chronic HCV Genotype I (n=865)
• 18 years or older
• No prior HCV treatment
• Patients with cirrhosis accepted (up to 20% of patients)
Afdhal N, et al. N Engl J Med. 2014;370:1889-98.
![Page 16: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/16.jpg)
Harvoni® - ledipasvir/sofosbuvir
Literature Review
ION-1
Afdhal N, et al. N Engl J Med. 2014;370:1889-98.
12 week treatment
24 week treatment
![Page 17: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/17.jpg)
Harvoni® - ledipasvir/sofosbuvir
Literature Review
ION-1
Afdhal N, et al. N Engl J Med. 2014;370:1889-98.
12 week treatment
24 week treatment
*Subgroup results do not include patients who withdrew consent or were lost to follow-up
![Page 18: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/18.jpg)
Harvoni® - ledipasvir/sofosbuvir
Literature Review
ION-1
•Conclusions:• “Once daily ledipasvir/sofosbuvir with or
without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.”
Afdhal N, et al. N Engl J Med. 2014;370:1889-98.
![Page 19: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/19.jpg)
Harvoni® - ledipasvir/sofosbuvir
Summary
• Harvoni® is indicated for the treatment of chronic hepatitis C genotype 1 infection in adults
• The use of Harvoni® with P-gp inducers is not recommended
• Harvoni® has a convenient dosing schedule which may increase compliance
![Page 20: Harvoni ® ledipasvir/sofosbuvir Manufacturer: Gilead Sciences FDA Approval Date: 10/10/2014.](https://reader033.fdocuments.net/reader033/viewer/2022061517/56649d745503460f94a543a1/html5/thumbnails/20.jpg)
Harvoni® - ledipasvir/sofosbuvir
References
1. Harvoni package insert. Gilead. October 2014. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
2. http://www.harvoni.com/ November 2014.
3. UPDATE 2 - US FDA approves Gilead’s $94,500 hepatitis C drug. Reuters. October 2014. (http://www.reuters.com/article/2014/10/10/gilead-fda-hepatitis-idUSL2N0S51WN20141010)
4. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98.